NCT06463743RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS): Randomized, Placebo-controlled Pilot Study.
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn: * The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo * How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period * The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 22 May 2024
- Start date
- 24 Sept 2025
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Multiple sclerosis
- NCT number
- NCT06463743
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 24 Sept 2025 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- diabetes or uncontrolled cardiovascular disease
Other
- inability to undergo MRI scans
- inability to participate in the study during the study period
- unable to consent
Who the study is looking for
- age between 55 and 75 years old
- having a diagnosis of MS based on the latest McDonald criteria
- non-active disease course (no relapses and no MRI activity) in the last 2 years as determined by the MS provider and based on the 2020 revised clinical course criteria
- EDSS score \<7.0
Age in the registry: 55 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UBMD Neurolgy Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.